This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Beckman Coulter Receives CE Mark
Tech medical breakthrough

Beckman Coulter Receives CE Mark

Analysis based on 7 articles · First reported Apr 13, 2026 · Last updated Apr 13, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The approval of the Access MeMed BV assay by Danaher Corporation — Beckman Coulter is expected to positively impact the diagnostics market by offering a faster and more accurate method for differentiating bacterial and viral infections. This innovation could lead to significant cost savings for European healthcare systems, potentially reducing unnecessary admissions and antibiotic use, which benefits both Danaher Corporation — Beckman Coulter and its parent company Danaher Corporation.

Healthcare Biotechnology Medical Devices
Event Summary

Danaher Corporation — Beckman Coulter Diagnostics, a subsidiary of Danaher Corporation, has received CE 2797 mark under IVDR for its Access MeMed BV assay. This approval allows for the widespread availability of a high-throughput host-response test in Europe, which can differentiate between bacterial and viral infections in approximately 20 minutes. The Access MeMed BV assay, developed in partnership with MeMed, is validated for use on Danaher Corporation — Beckman Coulter's DxI 9000 and Access 2 immunoassay analyzers. Economic modeling suggests that the adoption of this assay could reduce up to €80 million in avoidable costs across European healthcare systems by decreasing unnecessary admissions and diagnostic testing. This development is poised to enhance clinical decision-making, curb unnecessary antibiotic use, and advance antimicrobial stewardship initiatives.

Entities Involved
priv
MeMed
MeMed partnered with Danaher Corporation — Beckman Coulter to bring its MeMed BV test into core laboratory settings, significantly accelerating its mission to make host-response testing available at scale and improving its market presence.
Importance 90.0 Sentiment 75.0
subs
Danaher Corporation — Beckman Coulter
Danaher Corporation — Beckman Coulter, a subsidiary of Danaher Corporation, received CE 2797 mark for its Access MeMed BV assay, enabling broad availability of the test in Europe. This development is expected to enhance its market position in diagnostics.
Importance 90.0 Sentiment 70.0
stock
Danaher Corporation
Danaher Corporation, as the parent company of Danaher Corporation — Beckman Coulter, benefits from the CE mark approval of the Access MeMed BV assay, which expands its diagnostics portfolio and market reach in Europe.
Importance 70.0 Sentiment 60.0
per
Melissa Naiman
Melissa Naiman, Medical & Scientific Affairs at Danaher Corporation — Beckman Coulter Diagnostics, commented on the benefits of the new assay for care teams and laboratory efficiency.
Importance 10.0 Sentiment 0.0
per
Eran Eden
Eran Eden, CEO & Co-founder of MeMed, highlighted the collaboration with Danaher Corporation — Beckman Coulter as a significant step in making host-response testing widely available.
Importance 10.0 Sentiment 0.0
loc
Europe
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.